Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Conley

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
The Psychiatric Clinics of North America|December 1, 2009
The burden of depressive symptoms in people with schizophreniaRobert R Conley
Schizophrenia Research|August 2, 2003
Evaluating sexual function in patients with treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley
Schizophrenia Bulletin|June 15, 2005
Sexuality and schizophrenia: a reviewDeanna L Kelly, Robert R Conley
Psychoneuroendocrinology|October 4, 2005
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophreniaDeanna L Kelly, Robert R Conley
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Current status of antipsychotic treatmentRobert R Conley, Deanna L Kelly
The Journal of Clinical Psychiatry|January 27, 2005
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazineDeanna L Kelly, Robert R Conley
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
The American Journal of Psychiatry|December 7, 2007
Challenge to atypical antipsychotic drug effect on cognitionWilliam T Carpenter, Robert R Conley
Statistics in Medicine|October 30, 2004
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at riskRobert P McMahon, Stephan Arndt, Robert R Conley
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
The Psychiatric Clinics of North America|December 1, 2009
The burden of depressive symptoms in people with schizophreniaRobert R Conley
Schizophrenia Research|August 2, 2003
Evaluating sexual function in patients with treatment-resistant schizophreniaDeanna L Kelly, Robert R Conley
Schizophrenia Bulletin|June 15, 2005
Sexuality and schizophrenia: a reviewDeanna L Kelly, Robert R Conley
Psychoneuroendocrinology|October 4, 2005
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophreniaDeanna L Kelly, Robert R Conley
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Current status of antipsychotic treatmentRobert R Conley, Deanna L Kelly
The Journal of Clinical Psychiatry|January 27, 2005
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazineDeanna L Kelly, Robert R Conley
Psychopharmacology Bulletin|February 8, 2007
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patientsRobert R Conley, Deanna L Kelly
The Israel Journal of Psychiatry and Related Sciences|September 2, 2005
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effectsRobert R Conley, Deanna L Kelly
The American Journal of Psychiatry|December 7, 2007
Challenge to atypical antipsychotic drug effect on cognitionWilliam T Carpenter, Robert R Conley
Statistics in Medicine|October 30, 2004
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at riskRobert P McMahon, Stephan Arndt, Robert R Conley
Pageof 12